Open Label Study of Erlotinib (Tarceva) as Single Agent First Line Treatment of Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With Activating Epidermal Growth Factor Receptor (EGFR) Mutations.

Trial Profile

Open Label Study of Erlotinib (Tarceva) as Single Agent First Line Treatment of Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With Activating Epidermal Growth Factor Receptor (EGFR) Mutations.

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Feb 2016

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 09 Mar 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 10 Feb 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 03 Feb 2014 Planned End Date changed from 1 Dec 2015 to 1 Jan 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top